Kaken Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Kaken Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kaken Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kaken Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kaken Pharmaceutical Co Ltd (Kaken) is a pharmaceutical company. It develops and markets prescription pharmaceutical drugs, agrochemicals, medical equipment and products related to animal health. The company offers solutions in the fields of orthopedics, dermatology, inflammation, allergy, fungal infections and pain relief. Kaken offers fungicides, rice herbicides, feed additives for chicken and veterinary drugs. The company also offers real estate rental services. The company's products focus on new drugs, particularly in the fields of dermatology and orthopedics, and a natural pesticide called Polyoxin. The company's products cater to healthcare providers and agricultural industries. It markets products through license and distribution agreements with companies in the US, Canada, Taiwan, China, South Korea, Israel and Jordan and operates sales offices in various places in Japan. Kaken is headquartered in Bunkyo-ku, Tokyo, Japan.
Headquarters
Japan
Address
2-28-8 Honkomagome, Bunkyo-Ku, Tokyo, 113-8650
Website
www.kaken.co.jp
Telephone
81 3 59775001
No of Employees
1,114
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4521 (TYO)
Revenue (2025)
$494.0M
-18.3%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-84.6%
(2025 vs 2024)
Market Cap*
$1.0B
Net Profit Margin (2025)
XYZ
-81.2%
(2025 vs 2024)
* As of and is in US$
Kaken Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Prescription Pharmaceuticals | Real Estate Leasing | Artz |
| Agrochemicals | Procylin | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company secured approval from the Ministry of Health, Labor and Welfare in Japan for EKTERLY (sebetralstat), a novel plasma kallikrein inhibitor. |
| 2025 | Contracts/Agreements | In November, the company and Numab Therapeutics AG entered into a licensing and co-development agreement for NM81, a multispecific antibody for the treatment of inflammatory bowel disease. |
| 2025 | Contracts/Agreements | In August, the company entered into an agreement with Astria Therapeutics Inc to develop and commercialize Navenibart for hereditary angioedema in Japan. |
Competitor Comparison
| Key Parameters | Kaken Pharmaceutical Co Ltd | Daiichi Sankyo Co Ltd | Eisai Co Ltd | Sawai Pharmaceutical Co Ltd | Tanabe Pharma Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Bunkyo-Ku | Chuo-Ku | Bunkyo-Ku | Yodogawa | - |
| State/Province | Tokyo | Tokyo | Tokyo | Osaka | Osaka |
| No. of Employees | 1,114 | 19,765 | 10,543 | 2,634 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Hiroyuki Horiuchi | Chief Executive Officer; President; Director | Executive Board | 2020 | 64 |
| Masaru Suzuki | Managing Director; Director; Head - International Business Division | Executive Board | 2025 | 64 |
| Mitsuru Watanuki | Head-Research and Development; Director | Executive Board | 2023 | 62 |
| Akemi Okuyama | Head - Pharmaceutical Affairs Division, Production Division, General Affairs Department, and Information Provision Activities Supervision Office; Director | Executive Board | 2025 | 59 |
| Tatsuhiro Harada | Deputy General Manager - Research and Development; General Manager - New Drug Discovery Center | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer